An insulin pen is a device that administers insulin to diabetic individuals. Patients with type 1 diabetes choose to use it for therapy, making it easy to inject insulin into the body. Insulin pen needles are thinner and shorter than those used in syringes.
New York, Nov. 03, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Insulin Pen Market, Users, Global Forecast 2023-2027, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis” – https://www.reportlinker.com/p06359423/?utm_source=GNW
It also gives more exact dosing and less pain than vials and syringes, and clinicians and patients prefer it. Furthermore, the insulin pen improves the quality of life and minimizes the dread of hyperglycaemia. The low cost of an insulin pen makes it more accessible to people of all ages. However, insulin pens should not be shared since infections like hepatitis can be transmitted.
Major Market Trends Shaping the Insulin Pen Market Worldwide:
With the high base of the aging population, which causes diabetes, the global insulin pen market has the enormous potential over time. As a result, manufacturers are concentrating their measures on the Asian market to meet the demand for insulin pen devices. The rising prevalence of diabetes among people of various ages is a major factor driving the global insulin pen market. In addition, the insulin pen industry is benefiting from increased R&D activity. However, concerns over infusion pen safety and strict regulations for new product development are limiting the expansion of the insulin pen business. As a result, Global Insulin Pen Market Size is dexpanding with a CAGR Of 5.18% During 2022-2027.
COVID-19 Impact Analysis on Global Insulin Pen Industry:
According to the IDF, people with diabetes were more likely to acquire COVID-19 disease and have severe symptoms. As a result, demand for insulin pens use soared during the COVID-19 pandemic. As a result, the homecare insulin pen business exploded worldwide due to the epidemic. Furthermore, demand for automated and efficient insulin pens soared throughout the epidemic. Moreover, as per our analysis, Global Insulin Pen Market will reach US$ 50.84 Billion in 2021.
Segment Analysis in Global Insulin Pen Market:
The Global Global Insulin Pump Market is studied in the United States, United Kingdom, Israel, Germany, Netherlands, Sweden, France, Switzerland, Australia, Japan, Canada, Kuwait, Saudi Arabia, Italy, and Spain. Further, the market in detail is categorized based on Diabetes Population (Type 1 and Type 2), Insulin Pump Market Analysis (Insulin Pump User (Type 1 and Type 2) & Insulin Pump Market (Type 1 and Type 2)), and Reimbursement Policies on Insulin Pump.
The global Insulin Pump Market is competitive, with only a few businesses competing. Among the major players covered in our study are B. Braun Melsungen AG, Eli Lilly and Company, Becton, Dickinson (BD), Novo Nordisk A/S, Ypsomed AG, and Terumo Corporation. These firms control a significant portion of the global market. In addition, they are constantly expanding into new markets to produce new revenue streams and improve existing ones. These market actors’ actions will foster competition, forcing enterprises to experiment with the latest technology to differentiate their products. Companies are also partnering to improve their technical understanding and save product development time.
This latest report “Insulin Pen Market, Global Forecast, By Types Disposable Insulin Pen, Reusable Insulin Pen, Smart Insulin Pen and Insulin Pen Needle), Countries (United States, India, China, Brazil, Saudi Arabia, United Kingdom, Germany, Netherlands, Sweden, Switzerland and Australia), Country Insights (Diabetes Population (Type 1 and Type 2), Market & User Analysis (Insulin Pen Market and Insulin Pen User), Types (Disposable Insulin Pen, Reusable, Smart Insulin Pen and Insulin Pen Needle Market and Reimbursement Policies), Companies (B. Braun Melsungen AG, Eli Lilly and Company, Becton, Dickinson (BD), Novo Nordisk A/S, Ypsomed AG and Terumo Corporation)” provides a detailed analysis of Global Insulin Pen Industry.
Types – The market has been covered from 4 viewpoints:
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle
Country – The market has been covered from 11 viewpoints:
1. United States
5. Saudi Arabia
6. United Kingdom
The above-mentioned countries have been covered from 4 viewpoints:
1. Diabetes Population
• Type 1
• Type 2
2. Market & User Analysis
• Insulin Pen Market
• Insulin Pen User
3. Types – Insulin Pen Market & Users
• Disposable Insulin Pen
• Reusable Insulin Pen
• Smart Insulin Pen
• Insulin Pen Needle Market
4. Reimbursement Policies
• Recent Development
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Becton, Dickinson(BD)
4. Novo Nordisk A/S
5. Ypsomed AG
6. Terumo Corporation
Read the full report: https://www.reportlinker.com/p06359423/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
Chimera (CIM) delivered earnings and revenue surprises of 8% and 1.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com users have recently been watching AGNC Investment (AGNC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), AT&T Inc. (T) and Lockheed Martin Corporation (LMT).
Recently, Zacks.com users have been paying close attention to Bed Bath & Beyond (BBBY). This makes it worthwhile to examine what the stock has in store.
In the latest trading session, Novavax (NVAX) closed at $20.17, marking a -1.61% move from the previous day.
Real estate investment trusts (REITs) are some of the best options for investors looking to generate stable dividend income. This is because publicly traded REITs are required to distribute at least 90% of their taxable income to shareholders annually, as per Securities and Exchange Commission (SEC) rules. The need for high-dividend-paying stocks is rising as the markets snap out of its latest relief rally resulting from poor earnings posted by tech titans. Even though the Dow Jones Industrial A
Motorola (MSI) delivered earnings and revenue surprises of 4.17% and 2.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Uniti (UNIT) delivered FFO and revenue surprises of 2.38% and 0.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings will be released after the bell, and investors are taking a cautious approach to the quarter.
Wall Street isn't bullish on every down stock, as evidenced by an average price target of 9.8% upside for Upstart stock.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Federal Realty Investment Trust (FRT) delivered FFO and revenue surprises of 3.25% and 4.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
In the latest trading session, Southern Copper (SCCO) closed at $48.40, marking a +0.85% move from the previous day.
Insight Enterprises (NSIT) delivered earnings and revenue surprises of 4.19% and 2.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) closed the most recent trading day at $2.65, moving -1.12% from the previous trading session.
CF (CF) delivered earnings and revenue surprises of -20.06% and 0.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
General Mills (GIS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Recently, Zacks.com users have been paying close attention to PepsiCo (PEP). This makes it worthwhile to examine what the stock has in store.
Crescent Capital BDC (CCAP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recently, Zacks.com users have been paying close attention to Oracle (ORCL). This makes it worthwhile to examine what the stock has in store.